Table 1.
Demographic, anthropometric, and clinical data from post-COVID-19 patients based on disease severity classification during the acute phase, and demographic and anthropometric data from control subjects.
| Patients/ Controls |
* Gender (F/M) |
** Age (Mean ± SD) |
*** BMI (kg/m2) |
§ Total SARS-CoV-2 Antibodies |
− CRP (mg/dL) |
+ Days Post-COVID-19 Mean |
|---|---|---|---|---|---|---|
| Asymptomatic N = 10 (6.7%) |
8 F (80%) 2 M (20%) |
36.5 ± 13.8 | 26.5 ± 4.7 | 29.2 ± 49.1 | 0.42 ± 0.27 | 72 (~10 weeks) (~2.4 months) |
| Mild N = 117 (78.5%) |
78 F (66.7%) 39 M (33.3%) |
40.4 ± 14.1 | 27.9 ± 5.0 | 68.6 ± 58.8 p = 0.047 |
0.56 ± 0.92 | 84 (~12 weeks) (~2.8 months) |
| Moderate N = 10 (6.7%) |
7 F (70%) 3 M (30%) |
49.6 ± 13.4 | 35.2 ± 5.3 p < 0.001 |
101.1 ± 57.5 p = 0.006 |
1.56 ± 1.68 | 81 (~11.5 weeks) (~2.7 months) |
| Severe N = 12 (8%) |
5 F (41.7%) 7 M (58.3%) |
43.7 ± 15.7 | 31.4 ± 4.7 p = 0.001 |
87.3 ± 43. 4 p = 0.032 |
3.22 ± 4.35 | 105 (~15 weeks) (~3.5 months) |
| Controls N = 71 |
51 F (71.8%) 20 M (28.2%) |
46.1 ± 16.6 | 26 ± 4.7 | ND | ND | NA |
F: female; M: male; SD: standard deviation; BMI: body mass index; kg/m2: kilograms per square meters; CRP: C-reactive protein; mg/dL: milligrams per deciliter; ND: not determined. NA: Not applicable. * p = 0.110; ** p = 0.986; *** p < 0.05 (Controls vs. Moderate/Severe); § p = 0.006 (Asymptomatic vs. Mild/Moderate/Severe); − p = 0.282; + p = 0.505.